Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes Marseille, France; Department of Life Sciences, University of Science and Technology of Hanoi (USTH), Hanoi, Vietnam.
Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes Marseille, France.
Trends Biochem Sci. 2021 May;46(5):351-365. doi: 10.1016/j.tibs.2020.11.010. Epub 2020 Nov 27.
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently creating a global health emergency. This crisis is driving a worldwide effort to develop effective vaccines, prophylactics, and therapeutics. Nucleic acid (NA)-based treatments hold great potential to combat outbreaks of coronaviruses (CoVs) due to their rapid development, high target specificity, and the capacity to increase druggability. Here, we review key anti-CoV NA-based technologies, including antisense oligonucleotides (ASOs), siRNAs, RNA-targeting clustered regularly interspaced short palindromic repeats-CRISPR-associated protein (CRISPR-Cas), and mRNA vaccines, and discuss improved delivery methods and combination therapies with other antiviral drugs.
由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）大流行目前正在引发全球卫生紧急情况。这场危机正在推动全球努力开发有效的疫苗、预防药物和治疗药物。由于核酸（NA）疗法具有快速开发、高靶标特异性以及增加药物可及性的能力，因此在对抗冠状病毒（CoV）爆发方面具有巨大潜力。在这里，我们回顾了关键的抗 CoV NA 技术，包括反义寡核苷酸（ASO）、小干扰 RNA（siRNA）、靶向 RNA 的成簇规律间隔短回文重复序列-相关蛋白（CRISPR-Cas）和 mRNA 疫苗，并讨论了改进的递送方法和与其他抗病毒药物的联合疗法。
